Search research articles
Contact Us
Filters
Showing results (81-90 of 434) with videos related to
Page
of 44
Sort By:
Neuro-Oncology
|
August 29, 2014
The mTOR signaling pathway as a treatment target for intracranial neoplasms
Doreen Pachow, Wolfgang Wick, David H Gutmann, et al.
Genes & Development
|
August 15, 2015
Neurofibromatosis-1 regulation of neural stem cell proliferation and multilineage differentiation operates through distinct RAS effector pathways
Yi-Hsien Chen, Scott M Gianino, David H Gutmann
Cancer Epidemiology
|
March 29, 2016
Peri-gestational risk factors for pediatric brain tumors in Neurofibromatosis Type 1
Kimberly J Johnson, Nancy L Zoellner, David H Gutmann
Journal of Child Neurology
|
September 2, 2016
Macrocephaly Is Not a Predictor of Optic Pathway Glioma Development or Treatment in Neurofibromatosis Type 1
Stephanie M Morris, Courtney L Monroe, David H Gutmann
Journal of Attention Disorders
|
February 23, 2012
A neuropsychological perspective on attention problems in neurofibromatosis type 1
Alexandra K Templer, Jeffrey B Titus, David H Gutmann
The Journal of Clinical Investigation
|
April 6, 2006
Harnessing preclinical mouse models to inform human clinical cancer trials
David H Gutmann, Kim Hunter-Schaedle, Kevin M Shannon
Cancer Research
|
January 7, 2006
Mouse Models of Human Cancers Consortium Workshop on Nervous System Tumors
David H Gutmann, Elizabeth A Maher, Terry Van Dyke
Cancer Research
|
January 25, 2005
Glioma formation in neurofibromatosis 1 reflects preferential activation of K-RAS in astrocytes
Biplab Dasgupta, Wen Li, Arie Perry, et al.
The Journal of Investigative Dermatology
|
March 11, 2004
Piebaldism and neurofibromatosis type 1: horses of very different colors
Richard A Spritz, Peter H Itin, David H Gutmann
Cancer Cell
|
July 14, 2012
Innate neural stem cell heterogeneity determines the patterning of glioma formation in children
Da Yong Lee, Scott M Gianino, David H Gutmann
Page
of 44
Search research articles
Search
Showing results (81-90 of 434) with videos related to
Sort By:
Page
of 44
Neuro-Oncology
|
August 29, 2014
The mTOR signaling pathway as a treatment target for intracranial neoplasms
Doreen Pachow, Wolfgang Wick, David H Gutmann, et al.
Genes & Development
|
August 15, 2015
Neurofibromatosis-1 regulation of neural stem cell proliferation and multilineage differentiation operates through distinct RAS effector pathways
Yi-Hsien Chen, Scott M Gianino, David H Gutmann
Cancer Epidemiology
|
March 29, 2016
Peri-gestational risk factors for pediatric brain tumors in Neurofibromatosis Type 1
Kimberly J Johnson, Nancy L Zoellner, David H Gutmann
Journal of Child Neurology
|
September 2, 2016
Macrocephaly Is Not a Predictor of Optic Pathway Glioma Development or Treatment in Neurofibromatosis Type 1
Stephanie M Morris, Courtney L Monroe, David H Gutmann
Journal of Attention Disorders
|
February 23, 2012
A neuropsychological perspective on attention problems in neurofibromatosis type 1
Alexandra K Templer, Jeffrey B Titus, David H Gutmann
The Journal of Clinical Investigation
|
April 6, 2006
Harnessing preclinical mouse models to inform human clinical cancer trials
David H Gutmann, Kim Hunter-Schaedle, Kevin M Shannon
Cancer Research
|
January 7, 2006
Mouse Models of Human Cancers Consortium Workshop on Nervous System Tumors
David H Gutmann, Elizabeth A Maher, Terry Van Dyke
Cancer Research
|
January 25, 2005
Glioma formation in neurofibromatosis 1 reflects preferential activation of K-RAS in astrocytes
Biplab Dasgupta, Wen Li, Arie Perry, et al.
The Journal of Investigative Dermatology
|
March 11, 2004
Piebaldism and neurofibromatosis type 1: horses of very different colors
Richard A Spritz, Peter H Itin, David H Gutmann
Cancer Cell
|
July 14, 2012
Innate neural stem cell heterogeneity determines the patterning of glioma formation in children
Da Yong Lee, Scott M Gianino, David H Gutmann
Page
of 44